Top

Published in:

06-07-2021 | Anthracycline | Review Article

MIBG cardiac imaging compared to ejection fraction in evaluation of cardiotoxicity: a systematic review

Authors: Thaís Rossato Arrais, MD, MSc, Germano Dallegrave Cavalli, MD, Bárbara Tietbohl dos Santos, MD, Gabriela Bartzen Pereira, MD, Celina Borges Migliavaca, MD, Gabriel Blacher Grossman, MD, PhD, Andréia Biolo, MD, PhD

Published in: Journal of Nuclear Cardiology | Issue 5/2022

Abstract

Background

Advances in diagnosis and treatment of cancer has improved survival but resulted in increased cardiotoxic effects. The decrease in left ventricular ejection fraction (EF), one of the pillars of diagnosis of cardiotoxicity, seems to be a late process in the evolution of the disease, so ^123I-metaiodobenzylguanidine (MIBG) cardiac imaging has been proposed to detect early cardiac impairment. The aim of this systematic review was to evaluate the performance of MIBG cardiac scan in this scenario.

Methods and Results

A systematic search was conducted in five international databases comparing MIBG parameters with EF for evaluation of cardiotoxicity. Twelve studies were included and separated in three groups. First, studies evaluating patients with established cardiotoxicity, in which EF was reduced and MIBG parameters were abnormal. Second, studies analyzing patients during or after treatment compared to controls, with MIBG parameters significantly different between groups in most studies, even when EF remained normal. Finally, studies analyzing anthracycline (ATC) dose-related changes, with alteration in MIBG parameters occurring even when EF was preserved.

Conclusion

Although studies had high methodological variability, cardiac sympathetic innervation imaging seems to be a promising tool for assessing early cardiotoxicity. Further studies are needed to analyze its diagnostic value in this scenario.

Available only for authorised users

Moser EC, Meunier F. Cancer survivorship: a positive side-effect of more successful cancer treatment. Eur J Cancer Suppl 2014;12(1):1-4.CrossRef

Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009;53(24):2231-47.PubMedCrossRef

Jiji RS, Kramer CM, Salerno M. Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs. J Nucl Cardiol 2012;19(2):377-88.PubMedPubMedCentralCrossRef

Panjrath GS, Jain D. Monitoring chemotherapy-induced cardiotoxicity: role of cardiac nuclear imaging. J Nucl Cardiol 2006;13(3):415-26.PubMedCrossRef

Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer Interdisciplinary Int J Am Cancer Soc 2003;97(11):2869-79.

Rocha ETD, Alves WEFM, Verschure DO, Verberne HJ. The use of cardiac 123I-mIBG scintigraphy in clinical practice: the necessity to standardize! Int J Cardiovas Sci 2017;30(6):533-41.

Mason JW, Bristow MR, Billingham ME, Daniels JR. Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat Rep 1978;62(6):857-64.PubMed

Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004;109(22):2749-54.PubMedCrossRef

Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010;28(25):3910-6.PubMedCrossRef

10.

Ky B, Putt M, Sawaya H, French B, Januzzi JL, Sebag IA, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol 2014;63(8):809-16.PubMedCrossRef

11.

Anthony FY, Ky B. Roadmap for biomarkers of cancer therapy cardiotoxicity. Heart 2016;102(6):425-30.CrossRef

12.

Filho RK, Hajjar LA, Bacal F, Hoff MGP, Diz MDPE, Galas FRBG, et al. I Diretriz Brasileira de Cardio-Oncologia da Sociedade Brasileira de Cardiologia [I Brazilian Guideline for Cardio-Oncology from Sociedade Brasileira de Cardiologia]. Arq Bras Cardiol 2011;96(2 Suppl 1):1-52.CrossRef

13.

Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016;37(36):2768-801.PubMedCrossRef

14.

Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American society of clinical oncology clinical practice guideline. J Clin Oncol 2016;35(8):893-911.PubMedCrossRef

15.

Ewer MS, Ali MK, Mackay B, Wallace S, Valdivieso M, Legha SS, et al. A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. J Clin Oncol 1984;2(2):112-7.PubMedCrossRef

16.

Aleman BM, Moser EC, Nuver J, Suter TM, Maraldo MV, Specht L, et al. Cardiovascular disease after cancer therapy. Eur J Cancer Suppl 2014;12(1):18-28.CrossRef

17.

Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: A systematic review. Journal of the American College of Cardiology 2014;63(25 Part A):2751-68.PubMedCrossRef

18.

Oikonomou EK, Kokkinidis DG, Kampaktsis PN, Amir EA, Marwick TH, Gupta D, et al. Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis. JAMA cardiology 2019;4(10):1007-18.PubMedPubMedCentralCrossRef

19.

Carrió I, Estorch M, Berná L, López-Pousa J, Tabernero J, Torres G. Indium-111-antimyosin and iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity. J Nucl Med 1995;36(11):2044-9.PubMed

20.

Carrió I, Lopez-Pousa A, Estorch M, Duncker D, Berná L, Torres G. Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies. J Nucl Med 1993;34(9):1503-7.PubMed

21.

Estorch M, Carrió I, Berná L, Martínez-Duncker C, Alonso C, Germá JR, et al. Indium-111-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer. J Nucl Med 1990;31(12):1965-9.PubMed

22.

Takeishi Y, Sukekawa H, Sakurai T, Saito H, Nishimura S, Shibu T, et al. Noninvasive identification of anthracycline cardiotoxicity: Comparison of 123 I-MIBG and 123 I-BMIPP imaging. Ann Nucl Med 1994;8(3):177-82.PubMedCrossRef

23.

D’Amore C, Gargiulo P, Paolillo S, Pellegrino AM, Formisano T, Mariniello A, et al. Nuclear imaging in detection and monitoring of cardiotoxicity. World J Radiol 2014;6(7):486.PubMedPubMedCentralCrossRef

24.

Nakata T, Nakajima K, Yamashina S, Yamada T, Momose M, Kasama S, et al. A pooled analysis of multicenter cohort studies of 123I-m IBG imaging of sympathetic innervation for assessment of long-term prognosis in heart failure. JACC Cardiovasc Imaging 2013;6(7):772-84.PubMedCrossRef

25.

Sawyer DB, Peng X, Chen B, Pentassuglia L, Lim CC. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog Cardiovasc Dis 2010;53(2):105-13.PubMedPubMedCentralCrossRef

26.

de Geus-Oei LF, Mavinkurve-Groothuis AM, Bellersen L, Gotthardt M, Oyen WJ, Kapusta L, et al. Scintigraphic techniques for early detection of cancer treatment–induced cardiotoxicity. J Nucl Med 2011;52(4):560-71.PubMedCrossRef

27.

Wakasugi S, Fischman AJ, Babich JW, Aretz HT, Callahan RJ, Nakaki M, et al. Metaiodobenzylguanidine: Evaluation of its potential as a tracer for monitoring doxorubicin cardiomyopathy. J Nucl Med 1993;34(8):1283-6.PubMed

28.

Wakasugi S, Wada A, Hasegawa Y, Nakano S, Shibata N. Detection of abnormal cardiac adrenergic neuron activity in adriamycin-induced cardiomyopathy with iodine-125-metaiodobenzylguanidine. J Nucl Med 1992;33(2):208-14.PubMed

29.

Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151(4):264-9.PubMedCrossRef

30.

Laursen AH, Ripa RS, Hasbak P, Kjær A, Elming MB, Køber L, et al. 123 I-MIBG for detection of subacute doxorubicin-induced cardiotoxicity in patients with malignant lymphoma. J Nucl Cardiol 2018;27(3):931-9.PubMedCrossRef

31.

Lekakis J, Prassopoulos V, Athanassiadis P, Kostamis P, Moulopoulos S. Doxorubicin-induced cardiac neurotoxicity: study with iodine 123-labeled metaiodobenzylguanidine scintigraphy. J Nucl Cardiol 1996;3(1):37-41.PubMedCrossRef

32.

Olmos RA, Willem W, Dewit LG, Hoefnagel CA, Liem H, van Tinteren H. Iodine-123 metaiodobenzylguanidine in the assessment of late cardiac effects from cancer therapy. Eur J Nucl Med 1996;23(4):453-8.CrossRef

33.

dos Santos MJ, da Rocha ET, Verberne HJ, da Silva ET, Aragon DC, Junior JS. Assessment of late anthracycline-induced cardiotoxicity by 123 I-mIBG cardiac scintigraphy in patients treated during childhood and adolescence. J Nucl Cardiol 2017;24(1):256-64.PubMedCrossRef

34.

Stokkel MP, Boekhout A. I-123-MIBG myocardial imaging in trastuzumab-based cardiotoxicity: the first experience. Nucl Med Commun 2013;34(1):19-24.PubMedCrossRef

35.

Guimarães SL, Brandão SC, Andrade LR, Maia RJ, Markman Filho B. Hiperatividade Simpática Cardíaca Após Quimioterapia: Sinal Precoce de Cardiotoxicidade? Arq Bras Cardiol 2015;105(3):228-34.PubMedPubMedCentral

36.

Nousiainen T, Vanninen E, Jantunen E, Remes J, Kuikka J, Hartikainen J. Anthracycline-induced cardiomyopathy: long-term effects on myocardial cell integrity, cardiac adrenergic innervation and fatty acid uptake. Clin Physiol 2001;21(1):123-8.PubMedCrossRef

37.

Olmos RV, ten Bokkel Huinink WW, Ten Hoeve RF, Van Tinteren H, Bruning PF, Van Vlies B, et al. Assessment of anthracycline-related myocardial adrenergic derangement by [123I] metaiodobenzylguanidine scintigraphy. Eur J Cancer 1995;31(1):26-31.CrossRef

38.

Bulten BF, Verberne HJ, Bellersen L, Oyen WJ, Sabaté-Llobera A, Mavinkurve-Groothuis AM, et al. Relationship of promising methods in the detection of anthracycline-induced cardiotoxicity in breast cancer patients. Cancer Chemother Pharmacol 2015;76(5):957-67.PubMedPubMedCentralCrossRef

39.

Valdés RO, Greve JC, Hoefnagel CA. I-123 MIBG and serial radionuclide angiocardiography in doxorubicin-related cardiotoxicity. Clin Nucl Med 1992;17(3):163-7.CrossRef

40.

van der Pal HJ, van Dalen EC, Hauptmann M, Kok WE, Caron HN, van den Bos C, et al. Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study. Arch Intern Med 2010;170(14):1247-55.PubMed

41.

Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 2012;5(5):596-603.PubMedPubMedCentralCrossRef

42.

Negishi K, Negishi T, Hare JL, Haluska BA, Plana JC, Marwick TH. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr 2013;26(5):493-8.PubMedCrossRef

43.

Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure: results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 2010;55(20):2212-21.PubMedCrossRef

Title: MIBG cardiac imaging compared to ejection fraction in evaluation of cardiotoxicity: a systematic review
Authors: Thaís Rossato Arrais, MD, MSc
Germano Dallegrave Cavalli, MD
Bárbara Tietbohl dos Santos, MD
Gabriela Bartzen Pereira, MD
Celina Borges Migliavaca, MD
Gabriel Blacher Grossman, MD, PhD
Andréia Biolo, MD, PhD
Publication date: 06-07-2021
Publisher: Springer International Publishing
Keywords: Anthracycline
Trastuzumab
Cytostatic Therapy
Published in: Journal of Nuclear Cardiology / Issue 5/2022
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI: https://doi.org/10.1007/s12350-021-02610-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

MIBG cardiac imaging compared to ejection fraction in evaluation of cardiotoxicity: a systematic review

Abstract

Background

Methods and Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods and Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2022

Left ventricular non-compaction with normal myocardial perfusion

Nuclear imaging in cardiac paragangliomas: Diagnostic and follow-up

What is this image? 2022 image 2 result: Right atrial angiosarcoma detected with 13N-NH3 myocardial PET/CT and 18F-FDG PET/CT

Localization of myocardial FDG uptake for prognostic risk stratification in corticosteroid-naïve cardiac sarcoidosis

Radiopharmaceutical supply disruptions and the use of 99mTc-hydroxymethylene diphosphonate as an alternative to 99mTc-pyrophosphate for the diagnosis of transthyretin cardiac amyloidosis: An ASNC Information Statement

Imaging of cardiac fibroblast activation in a patient after acute myocardial infarction using 68Ga-FAPI-04